Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
91 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Pipeline Review, H2 2016', provides in depth analysis on Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted pipeline therapeutics. The report provides comprehensive information on the Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - The report reviews Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics and enlists all their major and minor projects - The report assesses Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) Overview 9 Therapeutics Development 10 Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Products under Development by Stage of Development 10 Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Products under Development by Therapy Area 11 Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Products under Development by Indication 12 Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Pipeline Products Glance 13 Late Stage Products 13 Early Stage Products 14 Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Products under Development by Companies 15 Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Products under Development by Universities/Institutes 18 Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Therapeutics Assessment 20 Assessment by Monotherapy/Combination Products 20 Assessment by Mechanism of Action 21 Assessment by Route of Administration 22 Assessment by Molecule Type 24 Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Companies Involved in Therapeutics Development 26 AC Immune SA 26 AFFiRiS AG 27 BioArctic Neuroscience AB 28 Biogen Inc 29 Genmab A/S 30 Neuropore Therapies Inc 31 nLife Therapeutics SL 32 Primary Peptides, Inc. 33 Proclara Biosciences Inc 34 Prothena Corp Plc 35 QR Pharma Inc 36 reMYND NV 37 Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Drug Profiles 38 ABL-301 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 AV-1947D - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 AV-1948D - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 AV-1949D - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 AV-1950D - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 AV-1950R - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 BAN-0805 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 BIIB-054 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 CLR-01 - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 DPC-003 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 Kenterin - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 Monoclonal Antibodies to Inhibit Tau, Amyloid Beta and Alpha-Synuclein for Neurodegenerative Diseases - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 Monoclonal Antibody to Inhibit Alpha-Synuclein for Parkinson's Disease - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 NLFPD-1233 - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 NPT-088 - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 NPT-20011 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 NPT-289 - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 NPT-3G - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 NPT100-18A - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 PD-01 - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 PD-03 - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 PD-04 - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 Posiphen - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 PP-003 - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 PRX-002 - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 quinpramine - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 ReS-12S - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 ReS-9S - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 Small Molecule to Inhibit Alpha-Synuclein and Lcn2 for Parkinson's Disease - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 Small Molecule to Inhibit Alpha-Synuclein for Parkinson's Disease - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 Small Molecules to Inhibit Alpha-Synuclein for Parkinson's Disease - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 trehalose - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 Vaccine to Target Alpha-Synuclein for Neurodegenerative Disease - Drug Profile 77 Product Description 77 Mechanism Of Action 77 R&D Progress 77 Vaccine to Target Alpha-Synuclein for Parkinson's Disease - Drug Profile 78 Product Description 78 Mechanism Of Action 78 R&D Progress 78 Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Dormant Projects 79 Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Featured News & Press Releases 81 Nov 18, 2016: Proclara Biosciences Awarded Part the Cloud Grant from Alzheimer's Association to Support Development of NPT088 for Alzheimer's Disease 81 Nov 16, 2016: Proclara Biosciences Announces Newly Issued U.S. Patents for its Core Technology Targeting Protein Misfolding Disorders 81 Nov 09, 2016: Prothena Reports Results from Phase 1b Study of PRX002 Demonstrating Robust Antibody CNS Penetration and Significant Reduction of Free Serum Alpha-synuclein in Patients with Parkinson's Disease 82 Sep 07, 2016: Proclara Biosciences Announces Initiation of Phase 1b Clinical Trial of NPT088 for Alzheimer's Disease 83 Mar 22, 2016: Neuropore Announces Successful Completion of Phase I with its Lead Compound NPT200-11 83 Aug 12, 2015: Neuropore Therapies Commences Phase 1 Clinical Trials 84 Jul 19, 2015: NeuroPhage's NPT088 Universally Targets Misfolded Proteins in Preclinical Studies Highlighted in Oral Session at the Alzheimer's Association International Conference 84 Jul 13, 2015: NeuroPhage to be Featured in Oral Session at the 2015 Alzheimer's Association International Conference 85 Jul 02, 2015: BIIB054 reached significant milestone 85 Jun 17, 2015: Prothena Presents Clinical Results Demonstrating Robust, Rapid Reduction in Levels of Free Serum Alpha-Synuclein of Up to 96% After Single Dose of PRX002, Novel Protein Immunotherapy for Parkinson's Disease 85 Jun 15, 2015: BioArctic Neuroscience Parkinson's disease program receives grant from VINNOVA 86 Jun 08, 2015: Prothena to Present Clinical Results From Its Phase 1 Single Ascending Dose Study of PRX002 at 19th International Congress of Parkinson's Disease and Movement Disorders 87 Apr 02, 2015: 2nd US patent granted on therapeutic antibodies for Parkinson's disease 87 Mar 19, 2015: Prothena Reports Robust Reduction of Free Serum Alpha-Synuclein of up to 96% After Single Dose of PRX002, a Novel Protein Immunotherapy for Parkinson's Disease 87 Mar 16, 2015: NeuroPhage to Present at 12th International Conference on Alzheimer's & Parkinson's Diseases 89 Appendix 90 Methodology 90 Coverage 90 Secondary Research 90 Primary Research 90 Expert Panel Validation 90 Contact Us 90 Disclaimer 91
List of Tables
Number of Products under Development for, H2 2016 10 Number of Products under Development by Therapy Area, H2 2016 11 Number of Products under Development by Indication, H2 2016 12 Comparative Analysis by Late Stage Development, H2 2016 13 Comparative Analysis by Early Stage Products, H2 2016 14 Number of Products under Development by Companies, H2 2016 15 Products under Development by Companies, H2 2016 16 Products under Development by Companies, H2 2016 (Contd..1) 17 Number of Products under Investigation by Universities/Institutes, H2 2016 18 Products under Investigation by Universities/Institutes, H2 2016 19 Assessment by Monotherapy/Combination Products, H2 2016 20 Number of Products by Stage and Mechanism of Action, H2 2016 21 Number of Products by Stage and Route of Administration, H2 2016 23 Number of Products by Stage and Molecule Type, H2 2016 25 Pipeline by AC Immune SA, H2 2016 26 Pipeline by AFFiRiS AG, H2 2016 27 Pipeline by BioArctic Neuroscience AB, H2 2016 28 Pipeline by Biogen Inc, H2 2016 29 Pipeline by Genmab A/S, H2 2016 30 Pipeline by Neuropore Therapies Inc, H2 2016 31 Pipeline by nLife Therapeutics SL, H2 2016 32 Pipeline by Primary Peptides, Inc., H2 2016 33 Pipeline by Proclara Biosciences Inc, H2 2016 34 Pipeline by Prothena Corp Plc, H2 2016 35 Pipeline by QR Pharma Inc, H2 2016 36 Pipeline by reMYND NV, H2 2016 37 Dormant Projects, H2 2016 79 Dormant Projects (Contd..1), H2 2016 80
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
